Version 1 undefined
Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes
AUTHOR CONTRIBUTIONS
Conceptualization, C.-L.H. and J.S.M.; Investigation and visualization, C.-L.H., J.A.G., C.-W.C., A.M.D., K.J., H.-C.K., K.C.L., A.G.-W.L., Y.L., J.M.S., D.W., P.O.B., C.K.H., N.V.J., J.L.-M., A.W.N., J.P., and D.A.; Writing – Original Draft, C.-L.H., J.A.G., D.W., P.O.B., C.K.H., N.V.J., and J.S.M; Writing - Reviewing & Editing, C.-L.H., J.A.G., D.W., P.O.B., N.W., C.K.H., N.V.J., J.A.M., I.J.F., and J.S.M.; Supervision, J.A.M., I.J.F. and J.S.M.Footnotes
COMPETING INTERESTS
N.W. and J.S.M. are inventors on U.S. patent application no. 62/412,703 (“Prefusion Coronavirus Spike Proteins and Their Use”). D.W., N.W. and J.S.M. are inventors on U.S. patent application no. 62/972,886 (“2019-nCoV Vaccine”). C.-L.H., J.A.G., J.M.S., C.-W.C., A.M.D., K.J., H.-C.K., D.W., P.O.B., C.K.H., N.V.J., N.W., J.A.M., I.J.F., and J.S.M. are inventors on U.S. patent application no. 63/032,502 (“Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof”).
REFERENCES
References
- 1. Peiris J. S. M. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361, 1319–1325 (2003).
- 2. Zaki A. M., Van Boheemen S., Bestebroer T. M., Osterhaus A. D. M. E. & Fouchier R. A. M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med.367, 1814–1820 (2012). [[PubMed]
- 3. Chan J. F. W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet395, 514–523 (2020).
- 4. Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395, 497–506 (2020).
- 5. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol.3, 237–261 (2016).
- 6. Siebert D. N., Bosch B. J., van der Zee R., de Haan C. A. M. & Rottier P. J. M. The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. J. Virol.77, 8801–8811 (2003).
- 7. Mille J. K. & Whittaker G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U. S. A.111, 15214–15219 (2014).
- 8. Hoffmann M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell181, 271–280.e8 (2020).
- 9. Wan Y., Shang J., Graham R., Baric R. S. & Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol.94, 1–9 (2020).
- 10. Zhou P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270–273 (2020).
- 11. Walls AC. et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl. Acad. Sci. U. S. A.114, 11157–11162 (2017). [Google Scholar]
- 12. Buchholz UJ. et al. Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U. S. A.101, 9804–9809 (2004). [Google Scholar]
- 13. Hofmann H. et al. S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients. J. Virol.78, 6134–6142 (2004).
- 14. Sanders RW. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog.9, e1003618 (2013). [Google Scholar]
- 15. Pallesen J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U. S. A.114, E7348–E7357 (2017).
- 16. Crank MC. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science (80-. ).365, 505–509 (2019). [[PubMed][Google Scholar]
- 17. Park YJ. et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol.26, 1151–1157 (2019). [Google Scholar]
- 18. Li Z. et al. The human coronavirus HCoV-229E S-protein structure and receptor binding. Elife8, 1–22 (2019).
- 19. Wang N. et al. Structural Definition of a Neutralization-Sensitive Epitope on the MERSCoV S1-NTD. Cell Rep. 28, 3395–3405.e6 (2019).
- 20. Walls AC. et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell176, 1026–1039.e15 (2019). [Google Scholar]
- 21. Wrapp D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-. ).367, 1260–1263 (2020).
- 22. Walls AC. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell181, 281–292.e6 (2020). [Google Scholar]
- 23. McLellan JS. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science342, 592–598 (2013). [Google Scholar]
- 24. Rutten L. et al. A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. Cell Rep.23, 584–595 (2018).
- 25. Yang L. et al. Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage. Front. Immunol.9, 1631 (2018).
- 26. Joyce MG. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol.23, 811–820 (2016). [Google Scholar]
- 27. Krarup A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun.6, 8143 (2015).
- 28. Rutten L. et al. Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Rep.30, 4540–4550.e3 (2020).
- 29. Battles MB. et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun.8, 1528 (2017). [Google Scholar]
- 30. Qiao H. et al. Specific single or double proline substitutions in the ‘spring-loaded’ coiled-coil region of the influenza hemagglutinin impair or abolish membrane fusion activity. J. Cell Biol.141, 1335–1347 (1998).
- 31. Hastie KM. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science (80-. ).356, 923–928 (2017). [Google Scholar]
- 32. Impagliazzo A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science349, 1301–1306 (2015). [[PubMed]
- 33. Henderson R. et al. Controlling the SARS-CoV-2 Spike Glycoprotein Conformation. bioRxiv 2020.05.18.102087 (2020). doi:10.1101/2020.05.18.102087 [[PubMed]
- 34. Tegunov D& Cramer P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods16, 1146–1152 (2019). [Google Scholar]
- 35. Punjani A., Rubinstein J. L., Fleet D. J. & Brubaker M. A. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods14, 290–296 (2017). [[PubMed]
- 36. Ramírez-Aportela E. et al. Automatic local resolution-based sharpening of cryo-EM maps. Bioinformatics36, 765–772 (2020). [[PubMed]
- 37. Emsley P., Lohkamp B., Scott W. G. & Cowtan K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr.66, 486–501 (2010).
- 38. Liebschner D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. Sect. D Struct. Biol.75, 861–877 (2019).
- 39. Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Sect. D, Struct. Biol.74, 519–530 (2018). [Google Scholar]